Page last updated: 2024-10-28

hydralazine and Apoplexy

hydralazine has been researched along with Apoplexy in 16 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Research Excerpts

ExcerptRelevanceReference
" placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs."9.41The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021)
"This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke."7.81Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015)
" Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)."7.75Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009)
" Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine."7.74Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008)
"To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat."7.74Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008)
" Azelnidipine, hydralazine, or vehicle was orally administered for 28 days to stroke-prone spontaneously hypertensive rats."7.74Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. ( Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K, 2008)
" The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine."7.70Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999)
" placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs."5.41The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021)
" Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia."4.98Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018)
"Results suggest that perfusion can be augmented in ischemic stroke with norepinephrine and hydralazine."4.31Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study. ( Carroll, T; Christoforidis, GA; Jeong, YI; Liu, M; Niekrasz, M; Roth, S; Saadat, N, 2023)
"This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke."3.81Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015)
" Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)."3.75Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009)
" Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine."3.74Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008)
"To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat."3.74Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008)
" Azelnidipine, hydralazine, or vehicle was orally administered for 28 days to stroke-prone spontaneously hypertensive rats."3.74Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. ( Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K, 2008)
" We evaluated the effects of combining an angiotensin II type 1 (AT1) receptor blocker (ARB, valsartan) and a NEPI (CGS 25354) in comparison with a dual ACEI/NEPI (CGS 30440) in stroke-prone spontaneously hypertensive rats (SHRSP)."3.74Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. ( Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL, 2008)
" Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo."3.71Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001)
" The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine."3.70Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.25)18.7374
1990's1 (6.25)18.2507
2000's8 (50.00)29.6817
2010's3 (18.75)24.3611
2020's3 (18.75)2.80

Authors

AuthorsStudies
Liu, M1
Saadat, N1
Jeong, YI1
Roth, S1
Niekrasz, M1
Carroll, T1
Christoforidis, GA1
Carrera, JF1
Sorace, BJ1
Worrall, BB1
Southerland, AM1
Chiota-McCollum, NA1
Wiggers, H1
Køber, L1
Gislason, G1
Schou, M1
Poulsen, MK1
Vraa, S1
Nielsen, OW1
Bruun, NE1
Nørrelund, H1
Hollingdal, M1
Barasa, A1
Bøttcher, M1
Dodt, K1
Hansen, VB1
Nielsen, G1
Knudsen, AS1
Lomholdt, J1
Mikkelsen, KV1
Jonczy, B1
Brønnum-Schou, J1
Poenaru, MP1
Abdulla, J1
Raymond, I1
Mahboubi, K1
Sillesen, K1
Serup-Hansen, K1
Madsen, JS1
Kristensen, SL1
Larsen, AH1
Bøtker, HE1
Torp-Petersen, C1
Eiskjær, H1
Møller, J1
Hassager, C1
Steffensen, FH1
Bibby, BM1
Refsgaard, J1
Høfsten, DE1
Mellemkjær, S1
Gustafsson, F1
Watson, K1
Broscious, R1
Devabhakthuni, S1
Noel, ZR1
McKay, C1
Hall, AB1
Cortes, J1
Yee, J1
Yamamoto, E1
Tamamaki, N1
Nakamura, T2
Kataoka, K1
Tokutomi, Y1
Dong, YF1
Fukuda, M1
Matsuba, S1
Ogawa, H1
Kim-Mitsuyama, S1
Kato, N1
Liang, YQ1
Ochiai, Y1
Birukawa, N1
Serizawa, M1
Jesmin, S1
Konno, S1
Hirooka, Y2
Araki, S2
Koga, Y1
Kishi, T2
Sunagawa, K2
Yasukawa, K1
Utsumi, H1
NOZAWA, G1
HOSHINO, T1
Pu, Q1
Brassard, P1
Javeshghani, DM1
Iglarz, M1
Webb, RL1
Amiri, F1
Schiffrin, EL1
Smeda, J1
Vasdev, S1
King, SR1
Ikeda, Y1
Takano, H1
Kimura, H1
Obata, JE1
Takeda, S1
Hata, A1
Shido, K1
Mochizuki, S1
Yoshida, Y1
Nakaya, H1
Sasamura, H1
Hayashi, M1
Saruta, T1
Tejima, E1
Katayama, Y1
Suzuki, Y1
Kano, T1
Lo, EH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108]Phase 41,500 participants (Anticipated)Interventional2018-03-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for hydralazine and Apoplexy

ArticleYear
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
    Current hypertension reports, 2018, 06-08, Volume: 20, Issue:7

    Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri

2018

Trials

1 trial available for hydralazine and Apoplexy

ArticleYear
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
    American heart journal, 2021, Volume: 231

    Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H

2021

Other Studies

14 other studies available for hydralazine and Apoplexy

ArticleYear
Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study.
    Journal of neurointerventional surgery, 2023, Volume: 15, Issue:e1

    Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Dogs; Hydralazine; Infarction, Middle Cerebral

2023
Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:2

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Female; Fibrinolytic Ag

2020
Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2015, Volume: 47, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Female; Fib

2015
PGX: Pharmacogenomics During Generation X.
    Advances in chronic kidney disease, 2016, Volume: 23, Issue:2

    Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H

2016
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
    Stroke, 2008, Volume: 39, Issue:11

    Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressu

2008
Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:10

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida

2008
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Journal of cardiovascular pharmacology, 2008, Volume: 52, Issue:6

    Topics: Administration, Oral; Animals; Antihypertensive Agents; Antioxidants; Azetidinecarboxylic Acid; Bloo

2008
Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Brain; El

2009
[ON APOPLEXY IN A CERTAIN REGION AND THE PROPHYLACTIC USE OF ANTIHYPERTENSIVE AGENTS].
    [Chiryo] [Therapy], 1964, Volume: 46

    Topics: Adolescent; Antihypertensive Agents; Benzothiadiazines; Cerebrovascular Disorders; Child; Epidemiolo

1964
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Journal of hypertension, 2008, Volume: 26, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Ther

2008
Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:2

    Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Captopril;

1999
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    The Journal of laboratory and clinical medicine, 2000, Volume: 135, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv

2000
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
    Journal of the American Society of Nephrology : JASN, 2001, Volume: 12, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten

2001
Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model.
    Stroke, 2001, Volume: 32, Issue:6

    Topics: Animals; Blood Flow Velocity; Blood Gas Analysis; Blood Pressure; Brain; Cerebral Hemorrhage; Cerebr

2001